Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 23, 2026

Ocham's Razor Capital Limited Announces Reverse Takeover Transaction With Pelican Canada Inc. and Brokered Financing

View original at finance.yahoo.com
Ocham's Razor Capital Limited Announces Reverse Takeover Transaction With Pelican Canada Inc. and Brokered Financing NOT FOR DISTRIBUTION TO U.S…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Pelican operates in over 55 countries

    80% confidence
  • The resulting issuer will change its business to the current business of Pelican

    80% confidence
  • Pelican has over 25 years of experience in AI-driven payment processing and financial crime compliance

    80% confidence
  • Pelican has processed more than one billion transactions across various payment types and global banking standards

    80% confidence
  • The closing date of the offering is expected to occur on or about March 5, 2026

    80% confidence
  • Common shares of the Resulting Issuer issued to former holders of Subscription Receipts are anticipated to be free-trading, subject to applicable securities laws

    80% confidence
  • The net proceeds of the Offering will be used for working capital and general corporate purposes

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com